As a matter of tradition now, this 4th NP2D event will bring together a broad range of scientists from the academia and from the industry who share the same interest for peptide based drugs, even though they come from different horizons and from all around the world. Amongst all participants you will have a real chance to meet with renown scientist and key opinion leaders.

Below is a non-exhaustive list of participant/pre-registred delegations from major companies and institutes such as :

Aeterna Zentaris (Germany), Agricultural Research Organization (Israël), Airmid (USA), Almac Group (UK), Amazentis (Switzerland), Amgen (USA), Atheris Laboratories (Switzerland), Aveo Partners (Switzerland), Bachem (Switzerland), CEA-Saclay (France), Debiopharm (Switzerland), Debio RP (Switzerland), DSM Nutritional Products - Branch Pentapharm (Switzerland), Eli Lilly (USA), Estonian Biocenter (Estonia), F. Hoffmann-LaRoche (Switzerland), Fibrex Medical (Austria), Foothill Capital (Switzerland), Galderma (France), Genzyme Pharmaceuticals (USA) , IDRPHT (France), Kai Pharmaceuticals (USA), Karlsruhe Institute of Technology (Germany), Lonza (Switzerland), Mannkind Corporation (USA), Medicines for Malaria Venture (Switzerland), Medincell (France), Merck (USA), Mintaka Foundation for Medical Research (Switzerland), Novo Nordisk (Denmark), Novozymes (Denmark), Pepscan Therapeutics (Netherlands), Peptides & Elephants (Germany), Peptide Therapeutics Foundation (USA), Peptisyntha (Belgium), Pfizer (United Kingdom), Phylogica (Australia), Polyphor (Switzerland), Quality Assistance (Belgium), Roche Diagnostics (Germany), Sanofi-Aventis Pharmaceuticals (USA), Scientific Parc of Barcelona (Spain), Silanes Pharmaceuticals (Mexico), Solvay Group (Belgium), Swiss Insitute of Bioinformatics (Switzerland), Torrey Pines Institute (USA), Toxinomics Foundation (Switzerland) , TransMolecular (USA) Varleigh (UK), Venometech (France), Xenome (Australia), Xigen Pharma (Switzerland).

Major Universities and public institutions from all continents (Adelaide, Copenhagen, Florida, Frankfurt, Geneva, Hunan, Indiana, Leuven, Ljubljana, Oslo, Patras, Queensland, Sherbrooke, Singapore, South California, Stanford, Teheran, Vrije, etc.) will also be present with outstanding scientific contributions!

The following people are pre-registred, have already confirmed their attendence, and/or are members of the scientific committee:

• • Paul Alewood, University of Queensland, Australia
• • Miriam Altstein, Agricultural Research Organization, Israël
• • Maya Antonin, Atheris Laboratories, Switzerland
• • Mimoun Ayoub, Peptisyntha (Solvay Group), Belgium
• • Geert Baggerman, K.U. Leuven, Belgium
• • Amos Bairoch, Swiss Insitute of Bioinformatics, Switzerland
• • Kleomenis Barlos, University of Patras, Greece
• • Konstantinos Barlos, University of Patras, Greece
• • Kamel Besseghir, Debiopharm, Switzerland
  
• • Estelle Bianchi, Atheris Laboratories, Switzerland
• • Daniel Biass, Atheris Laboratories, Switzerland
• • Christophe Bonny, Xigen Pharma, Switzerland
• • Gerrit Borchard, University of Geneva, Switzerland
• • Daniel Bourgin, Lonza, Switzerland
• • Julio Camarero, University of South California, USA
• • Gregor Cevc, Idea AG, Germany
• • Jean-Christophe Chapelle, Quality Assistance, Belgium
• • Coralie De Almeida, Atheris Laboratories, Switzerland
• • Ram Dharanipragada, Sanofi-Aventis Pharmaceuticals, USA
• • Bertrand Ducrey, Debio RP, Switzerland
• • Philippe Dupraz, Amazentis, Switzerland
• • Rasmus Eliasen, Novo Nordisk, Denmark
  
• • Juergen Engel, Aeterna Zentaris, Germany
• • Emanuel Escher, University Sherbrooke, Canada
• • Pierre Escoubas, Venometech, France
  
• • Philippe Favreau, Atheris Laboratories, Switzerland
• • Patrick Garrouste, Debio RP, Switzerland
• • George Gaudriault, Medincell, France
• • Michel Geffard, IDRPHT, France
• • Daniel Gillet, CEA-Saclay, France
• • Matthieu Giraud, Lonza, Switzerland
• • Dan Hayden, Genzyme Pharmaceuticals, USA
• • Rainer Henning, Fibrex Medical, Austria
  
• • Kai Hilpert, Karlsruhe Institue of Technology, Germany
• • Eike Hoffmann, Roche Diagnostics, Germany
  
• • Peter Hoffmann, Genzyme Pharmaceuticals, USA
• • Kurt Hostettmann, University of Geneva, Switzerland
• • Maryse Hostettmann, Switzerland
• • Pamela Houghten, Torrey Pines Institute, USA
• • Richard Houghten, Torrey Pines Institute, USA
• • Irmgard Irminger-Finger, University of Geneva, Switzerland
• • Eric Kitas, F. Hoffmann-LaRoche Ltd, Switzerland
• • Dan Klaerke, University of Copenhagen, Denmark
• • Jacob Kofoed, Novo Nordisk, Denmark
• • Dominique Koua, Atheris Laboratories, Switzerland
  
• • Oliver Kreuzer, Peptides & Elephants, Germany
• • Silja Laht, Estonian Biocenter, Estonia
• • Bart Landuyt, K.U. Leuven, Belgium
• • Gildas Lavenant, Almac Group, France
• • Andrea Leone-Bay, Mannkind Corporation, USA
• • Songping Liang, Hunan Normal University, China
• • Derek Maclean , Kai Pharmaceuticals, USA
• • Pascale Mauvais, Galderma, France
  
• • John Mayer, Eli Lilly, USA
• • Dietrich Mebs, University of Frankfurt, Germany
• • Alexandre Melin, Medincell, France
  
• • Renée Ménez, Toxinomics Foundation, Switzerland
• • George Miljanich, Airmid LLC, USA
• • Les Miranda, Amgen, USA
• • Daria Mochly-Rosen, University of Stanford and founder of Kai Pharmaceuticals, USA
• • Hazel Montcrieff, Almac Group, France
  
• • Manfred Mutter, Debio RP, Switzerland
• • Jon Nissen-Meyer, University of Oslo, Norway
  
• • Daniel Obrecht, Polyphor, Switzerland
• • Robin Offord, Mintaka Foundation for Medical Research, Switzerland
• • Valérie Offord, Geneva, Switzerland
• • Araceli Olguin, Laboratorios Silanes, Mexico City, Mexico
• • Alain Razaname, Debio RP, Switzerland
• • Steffen Reedtz-Runge, Novo Nordisk, Denmark
• • Janice Reichert, Tufts University and Peptide Therapeutics Foundation, USA
• • Lee Roberts, Pfizer, United Kingdom
  
• • Manuella Schmitt-Billet, Polyphor, Switzerland
• • Ralph Schoenleber, Bachem, Switzerland
• • Dora Segura, Novozymes, Denmark
• • Abdellah Sentissi, TransMolecular Inc, USA
• • Reto Stöcklin, Atheris Laboratories, Switzerland
• • Sylvie Stöcklin, Atheris Laboratories, Switzerland
• • Peter Timmerman, Pepscan Therapeutics, The Netherlands
• • Dirk Tourwé, Vrije University, Belgium
• • Werner Tschollar, Aveo Partners, Switzerland
• • Judit Tulla-Puche, Scientific Parc of Barcelona, Spain
  
• • Géry Van Vyncht, Quality Assistance, Belgium
• • Aude Violette, Atheris Laboratories, Switzerland
• • Peter Verhaert, Delft University of Technology, The Netherlands
  
• • Paul Watt, Phylogica, Australia
• • Markus Weitzer, DSM Nutritional Products - Branch Pentapharm, Switzerland
• • Wynne Weston-Davies, Varleigh, United Kingdom
  
• • Julian White, Children's Hospital of Adelaide, Australia
• • Torsten Woehr, Genzyme Pharmaceuticals, USA
  

We are convinced that this will be an excellent opportunity for your organisation and give you access to great networking opportunities and we warmly encourage you to join us in Zermatt!